[HTML][HTML] Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics

F Yan, Z Wen, R Wang, W Luo, Y Du, W Wang… - BMC Pulmonary …, 2017 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is an irreversible interstitial pulmonary
disease featured by high mortality, chronic and progressive course, and poor prognosis with …

[HTML][HTML] There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF)

S Nambiar, B Clynick, BS How, A King, EH Walters… - Respiratory …, 2021 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease
characterized by fibrosis and progressive loss of lung function. The pathophysiological …

Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy

R Chen, J Dai - Journal of Molecular Medicine, 2023 - Springer
Idiopathic pulmonary fibrosis (IPF) is a chronic irreversible interstitial lung disease
characterized by a progressive decline in lung function. The etiology of IPF is unknown …

BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis

M d'Alessandro, L Bergantini, P Cameli, N Lanzarone… - Life Sciences, 2020 - Elsevier
Background Differential diagnosis between IPF and fibrotic HP (fHP) can be challenging:
these two ILDs share many common features but call for different therapeutic approaches. In …

Untargeted metabolomics of human plasma reveal lipid markers unique to chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis

S Nambiar, DBA Tan, B Clynick… - PROTEOMICS …, 2021 - Wiley Online Library
Chronic obstructive pulmonary disease (COPD) is characterised by airway inflammation and
progressive airflow limitation, whereas idiopathic pulmonary fibrosis (IPF) is characterised …

[HTML][HTML] Dysregulation of metabolic pathways in pulmonary fibrosis

R Rajesh, R Atallah, T Bärnthaler - Pharmacology & Therapeutics, 2023 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disorder of unknown origin and
the most common interstitial lung disease. It progresses with the recruitment of fibroblasts …

[HTML][HTML] Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication

B Seeliger, A Carleo, PD Wendel-Garcia… - Frontiers in …, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with significant mortality and
morbidity. Approval of antifibrotic therapy has ameliorated disease progression, but therapy …

[HTML][HTML] Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis–a potential biomarker role for LysoPC

B Rindlisbacher, C Schmid, T Geiser, C Bovet… - Respiratory …, 2018 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology.
Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires …

Analysis of tissue lipidomics and computed tomography pulmonary fat attenuation volume (CTPFAV) in idiopathic pulmonary fibrosis

M O'Callaghan, J Duignan, EJ Tarling, DK Waters… - …, 2023 - Wiley Online Library
Abstract Background and Objective There is increasing interest in the role of lipids in
processes that modulate lung fibrosis with evidence of lipid deposition in idiopathic …

Biomarkers in idiopathic pulmonary fibrosis

F Drakopanagiotakis, L Wujak, M Wygrecka, P Markart - Matrix Biology, 2018 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic, debilitating, fibrotic lung disease leading to
respiratory failure and ultimately to death. Being the prototype of interstitial lung diseases …